Background: Clinical and pathological parameters of patients with epithelial ovarian cancer (EOC) do not thoroughly predict patients' outcome. Despite the good outcome of stage I EOC compared with that of stages III and IV, the risk assessment and treatments are almost the same. However, only 20% of stage I EOC cases relapse and die, meaning that only a proportion of patients need intensive treatment and closer follow-up. Thus, the identification of cell mechanisms that could improve outcome prediction and rationalize therapeutic options is an urgent need in the clinical practice.
Differently from the advanced stages, the ESMO clinical practice guidelines admit different grades of stage I EOC surgical management, from the radical to the more conservative fertility-sparing surgery, whereas the administration of front-line chemotherapy is suggested only to intermediate-and high-risk patients [3] . However, the definition of patient risk is based on clinical and histopathological risk factors, such as the FIGO stage and grade, that, although helpful, have sensitivity and specificity completely unsatisfactory [4] . Thus, the definition of molecular changes responsible for a better definition of patient prognosis is an urgent need in clinical practice. In this direction, we have identified miR-200c-3p associated with poor prognosis of stage I patients [5] and, more recently, it has been shown that restoration of miR-200c-3p expression is a promising therapy due to its capability to affect tumor burden and chemosensitivity [6] .
Despite the convenience of a single-target strategy, it is increasingly clear that the tumor complexity and patient heterogeneity hamper the possibility of developing an effective one-shot therapy. In this perspective, not a single but multiple elements could improve early diagnosis and efficient personalized treatments.
Consistent with these notions, the aim of the current observational study is to better characterize EOC stage I molecular circuits involved in patient prognosis and improve the detection of patient risk at the time of diagnosis. methods patients A total of 203 snap-frozen tumor biopsies were gathered from three independent tumor tissue collections (A, B and C in Table 1 and supplementary Figure S1 , available at Annals of Oncology online). All biopsies were from patients who underwent complete surgical tumor removal and staging procedure, according to the FIGO (International Federation of Gynecologists and Obstetricians) guideline for the stage I EOC [7] (supplementary S2, available at Annals of Oncology online). The study has been carried out following the Declaration of Helsinki. The local scientific ethical committees approved the collection and usage of tumor samples. Written informed consent was obtained from all patients. The patients enrolled in the study did not receive standardized treatments, but interventions as part of their routine medical care.
materials
Microarray experiments were carried out following Agilent protocols [8, 9] (G4470B and G4851B), and raw data were submitted to the ArrayExpress database (E-MTAB-1067 and E-MTAB-1814). Microarray experiments were analyzed as in supplementary S3, available at Annals of Oncology online. The gene and miRNA expression integration have been studied using Micrographite [9] (supplementary S3, available at Annals of Oncology online). miRNA and gene expression levels in all the 203 biopsies were validated by RT-qPCR (supplementary S4, S5 and S6, available at Annals of Oncology online) [8] . Luciferase assay testing, the only predicted interaction between let-7e-5p and ACVR2B, has been carried out as reported in supplementary S4, available at Annals of Oncology online.
RT-qPCR expression measurements were tested for the association with overall survival (OS) and progression-free survival (PFS). Optimal cutpoints of expression have been calculated [10] , using the 'survMisc' R package, and differences in survival of patients belonging to the two groups were tested according to Kaplan-Meier (KM) and log-rank statistics, and Cox proportional hazards model in multivariate survival analyses (supplementary S7, available at Annals of Oncology online). The BenjaminiHochberg (BH) false discovery rate was used to correct P-values for multiple comparisons [11] . Genes and miRNAs have been selected as described in supplementary S8, available at Annals of Oncology online and illustrated in Table 2 . Optimal cut-off of the integrated signature classifier (ISC) has been calculated using a receiver operating characteristic (ROC) procedure and used to fit a multivariate survival model (supplementary S8, available at Annals of Oncology online).
Finally, all the reported procedures and strategies adopted are fully compliant with the Guidelines for the REporting of tumor MARKer Studies (REMARK; supplementary S1, available at Annals of Oncology online) and MIQE reports have been provided for RT-qPCR experiments (supplementary S4, available at Annals of Oncology online).
results

patient characteristics
Histopathological and clinical features of the 203 collected patients are summarized in Table 1 . We tested the clinic-and histopathology-based classifiers for association with OS and PFS using univariate and multivariate analyses. The analyses are reported in supplementary S2, available at Annals of Oncology online and they were similar to those reported in the literature [12, 13] for stage I EOC. Unlike stages III-IV, the relapse rate was low (∼20%-30%) and no significant differences in survival between histotypes can be appreciated. In addition, no genetic lesion (i.e. copy number variation, chromosomal structural variations promoter gene methylation defects or single-base substitutions) in driver genes, like BRCA1/2 or CCNE1, has been until now associated with prognosis in stage I EOC. In line with the literature, we have previously reported TP53 gene as wt in all stage I cases selected from B cohort [14, 15] . According to the ESMO guideline for the risk assessment in the early stage of EOC [4] , the tumor grade is the only variable that shows significant association with PFS only in univariate analysis. Retrospectively, in our cohort, the risk assessment procedure considering the only information about tumor grade has very low sensitivity and specificity (OS: 43% and 67%; PFS: 47% and 69%) and, similarly, using all the clinical and histopathological classifiers, it maintains poor sensitivity (OS: 53%, PFS: 65%) and has barely adequate specificity (OS: 74%, PFS: 72%; supplementary S2, available at Annals of Oncology online).
Detection of stage I EOC prognostic circuit
Since the tumor grade has been demonstrated to be the best proxy of survival among clinical annotations, we studied tumor samples of different grades to define the elements of the transcriptome with a prognostic value. The CONSORT diagram and study workflow are depicted in supplementary S1, available at Annals of Oncology online. The B1 cohort (Table 1 ; G1 = 17 and G3 = 17 patients) was profiled for gene and miRNA expressions using microarrays. We initially excluded clear cell patients to prevent histotype bias because all of them were diagnosed as G3. All the other clinical parameters were equally distributed (supplementary S2, available at Annals of Oncology online). The intrapatient expression variability penalizes the detection of differentially expressed genes (DEGs) and miRNAs (DEMs) leading to a small number of differentially expressed elements (13 DEM apparently not functionally related. Thus, the analysis of circuit has been carried out using Micrographite [9] that highlighted a circuit of 44 elements (23 miRNA and 21 genes) representing the optimal set of significant and consecutive relationships among genes and miRNAs able to discriminate G1 from G3 patients ( Figure 1 and supplementary S3, available at Annals of Oncology online). Figure 1 represents the identified circuit, which is composed of three functional parts: (i) cell cycle interactions (among them CCND1/2/3, CDK6/4 and CDKN1A/2A); (ii) Activins (ACVR1/ 1B/2B) and Inhibins (INHBA/B/C) and (iii) the Hedgehog signaling pathway with GLI family zinc finger transcription factors (GLI1/2/3). Notably, several miRNA-gene interactions mediate the crosstalk of these three pathways. The majority of the miRNAgene connections were already validated with reporter assays in previous studies and only one has been in silico predicted: the interaction between ACVR2B and hsa-let-7e-5p. Through luciferase and in vitro experiments, we confirmed the predicted functional anticorrelation between ACVR2B and hsa-let-7e-5p (supplementary S4, available at Annals of Oncology online).
Circuit expression status in the case of poor prognosis
Univariate and multivariate survival analyses were carried out using RT-qPCR expressions of the entire training set (n = 157). Results showed that 26 of 44 elements (10 genes and 16 miRNAs) were associated with patient prognosis in both OS and PFS (Table 2 and supplementary S7, available at Annals of Oncology online). Figure 1 shows survival analysis results mapped on the circuit. Colored nodes are prognostic and their colors reflect the expression status of poor prognosis patients. Worthy of note the expression concordances observed among functionally related The expression of each features was defined as 'high' or 'low' using an optimum cut-point derived on the score test of the Cox model. b q-value columns contain the P-values corrected for multiple testing, and a q-value lower than 0.01 was considered significant. The barcode column summarizes the 26 elements of the circuits that were considered (high or low, depending on their expression in the poor prognosis group) or not (no) for the ISC. The cut-point for hsa-miR-34a-5p defines a group with less than 20 patients this is considered unreliable and the feature discarded. OS, overall survival; PFS, progression-free survival; KM, Kaplan-Meier; ISC, integrated signature classifier. 
An integrated signature for risk detection in the training set
Using circuit and survival analysis data, we were able to derive the 'reference barcode of poor prognosis': 26 prognostic elements composed of 10 genes (three low and seven highly expressed) and 16 miRNAs (13 low and 3 highly expressed). Then, for each patient, we calculated the barcode represented by the expression status of the 26 prognostic elements in tumor biopsies at the time of the first surgery. Then, we compared the patient-specific barcode with the reference barcode generating an index of similarity called ISC: the number of concordances normalized by the total number of measured features. The ISC ranges from 0 to 1: the higher is the index, the is higher the similarity, the worst is the prognosis (details are given in supplementary S8, available at Annals of Oncology online). The expression cut-off of each elements is derived by an optimization procedure based on the survival model tested; thus, we have different cut-offs in case of OS or PFS and two ISCs for each patients (ISC-OS and ISC-PFS). Since OS and PFS represent different aspects of the clinical history of a patient, survival analyses and ISC calculation have been kept separate for OS and PFS. Both indexes were tested to improve the definition of patient risk. Figure 2 shows on the left side the reference barcode and each column of the heatmap represents a patientspecific barcode. The patients are ordered from left to right by increasing values of ISC-OS (Figure 2A ) and ISC-PFS ( Figure 2B ). No one patient shows a barcode identical to the reference (ISC = 1), the situation in which all the 26 features concordantly predict the poor prognosis, but all the patients showed different degree of similarity with the reference barcode (0.03 < ISC < 0.96). Above each heatmap, clinical and histopathological annotations and survival events are reported. It is evident that the majority of patients who experienced relapse and death by tumor could have been correctly identified at the time of diagnosis using ISC.
In addition, supplementary Table S8 .1, available at Annals of Oncology online summarizes the mean ISC of patients grouped by clinical annotations. The mean of both ISCs increases with tumor grade, it doubles in case of relapse, and it is comparable across tumor types and histotypes.
ROC curves were used to define the ISC cut-offs for the patient classification in high-/low-risk classes (supplementary Figures  S8.1 and S8. 2, available at Annals of Oncology online), and the discrimination capability of the classifier was assessed in terms of sensitivity and specificity and survival analyses. ISC-PFS of 0.45 was calculated as the cut-off for PFS ( Figure 2B ; OS P-value = 1.11e
−16
).
ISC in the risk assessment of an external and independent validation set
The expressions of the 26 prognostic features ( Figure 2C and D) were measured using RT-qPCR in patients of the validation set (n = 46). Patient-specific barcodes and ISC were calculated for each patient using the expressions cut-offs and ISC defined for the training set. Using ISC-PFS, we were able to predict the relapse and death of the patients with 75% sensitivity and 94.7% specificity (supplementary Tables S8.3 and 8. 4, available at Annals of Oncology online).
As well as in the training set, the KM analyses of the two classes of patients divided by risk were carried out ( Figure 3C and D), highlighting strong differences in survival confirmed by the log-rank test (PFS P-value = 6.74e −09 ; OS P-value = 2e
−07
). Moreover, the ISC classification of risk has been tested in a full multivariate model with all the anatomo-pathological and clinical annotations using the overall cohort of patients resulting the best classifier associated with OS (P-value lower than 1.23e −13 , supplementary S8, available at Annals of Oncology online) and PFS (P-value lower than 1e −16 , supplementary S8, available at Annals of Oncology online). We also obtained successful classification by risk among the patients treated with chemotherapy as well as among the untreated patients (supplementary S8, available at Annals of Oncology online).
Differently from stages III and IV, in which high-grade serous is the most clinically frequent histotype, the stage I EOC is generally characterized by heterogeneous histology; we therefore decided to assess if the ISC could be used to predict the patient risk of relapse and death in all the histotypes of stage I. To this aim, we repeated the entire procedure of analysis within each histotype, confirming that the prognostic power of ISC is histotype-independent (supplementary S9, available at Annals of Oncology online).
discussion
Integrated analysis of miRNA and coding transcripts expression revealed a circuit composed of 26 functionally related prognostic elements: 10 genes and 16 miRNAs. Among them, miR-200c-3p, a previously identified biomarker of prognosis of stage I EOC [5] , and a novel interaction (let-7e-5p with ACVR2B) was validated with a reporter assay.
Looking at the biological functions highlighted by the circuit, three functional subparts can be identified: cell cycle regulation, Activins/Inhibins and the Hedgehog pathways. These three pathways, strictly connected to the control of cell proliferation and tumor angiogenesis, have been previously associated with EOC [16] [17] [18] . Moreover, the Activins, due to their ability to sustain angiogenesis, are part of an emergent pathway for antiangiogenic therapies [16, [19] [20] [21] .
A mechanistic description of the network is beyond the scope of this paper; however, the circuit and its expressions jointly with survival data lead to assert that multiple signaling related to cell cycle and proliferation might be constitutively activated through multiple miRNA deregulations contributing to the poor prognosis of patients. In this respect, our findings tantalizingly suggest that drugs active on cell cycle regulation or Activins inhibitors could be effective candidates to be tested in stage I EOC. Concordantly, taken singularly, the miRNAs and genes of the circuit have been already associated with EOC (supplementary S10, available at Annals of Oncology online). Apart from the molecular and prognostic relevance of each single element, the main result of our study is that, taken together, the 10 genes and 16 miRNAs of the network can be used to define a patient-specific barcode to predict, at the time of diagnosis, the risk of relapse and poor survival. In a totally independent validation set, we were able to predict patient risk of relapse and death with a better resolution than what we obtain using the conventional anatomo-pathological and clinic-based classifiers.
Notably, although the majority of patients that we classified at high-risk would be classified so also using classical classifiers, our approach correctly identifies as 'high-risk', the grade 1 patients with poor prognosis, who were not selected for chemotherapy, and, as 'low-risk', the grade 2 and 3 patients with a good prognosis, invasively treated because considered at highrisk by the currently used risk classifier.
Analysis within histotypes from our series of tumor biopsies showed that the predictive value of ISC is shared across different histological subtypes. This suggests that, despite their different molecular specificities, other mechanisms, maybe related to the patient's genetic background or the common anatomical site of growth, are playing a key role in driving tumor prognosis. We have previously observed that the expression level of miR-200c-3p, which is one element of the ISC signature, was able to predict at diagnosis patient's outcome, independently of clinical and histological parameters [5] . These data are in line with and extend our previous findings on the prognostic role of miR200c-3p in stage I EOC. However, the fact that the prognostic value of ISC is independent of the patient histotype does not mean that differences in expression and survival across histotypes are not present and detectable, but simply suggests that the expressions of the 26 pathway elements include or at least well represent the histotype expressions related to prognosis.
In fact, the presence of histotype-specific expressions in stage I EOC has been already demonstrated: two miRNA markers for clear cell (miR-30a and miR-30a*) and a mucinous-specific circuit involving the miR-192/194 cluster [8, 9] . Moreover, three elements of the mucinous-specific circuit are shared with the prognostic barcode. Specifically, it has been observed that mucinous samples have lower expression of ACVR2B than other histotypes, due to the combined actions of miR-192/194 (highly expressed only in mucinous) and lower expression of CDK6 and CDK4 whereas high levels of ACVR2B, CDK6 and CDK4 are indications of poor prognosis in our barcode. This observation supports the theory that different histotypes could exhibits specific abilities to modulate the expressions of the 26 prognostic elements, and in the case of mucinous, high levels of miR-192/ 194 seem to be able to counteract the poorest prognostic signals causing a slightly better behavior that can be appreciated in the histotype survival analysis in supplementary S2, available at Annals of Oncology online and in the full Cox multivariate model reported in supplementary S8, available at Annals of Oncology online.
The data provided in this work broaden our current understanding of the stage I EOC biology and can be used to improve patient risk stratification at the time of diagnosis, suggesting new hints for the clinical management and the design of new combinatorial treatment protocols for patients with stage I EOC. We cannot exclude that future studies, aimed to explore the currently poorly investigated genomic landscape of stage I EOC, will provide novel molecular parameters that will be used to improve the prognostic role of this ISC.
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